4Schoder H, Noy A,Gonen M, et al. Intensity of ^18Fluorodeoxyglucose Uptake in Positron emission tomography distinguishes between indolent and aggressive non-hodgkin's Lymphoma J Clin Oncol, 2005,23 : 4643.
6Mclaughlin P. Progress and Promise in the treatment of indolent lymphomas. Oncologist, 2002,7: 217.
二级参考文献26
1[1]Harris N,Jaffe E,Stein H,et al.A revised European-Amreican classification of lymphoid neoplasms:A proposal from the International Lymphoma Study Group.Blood,1994,84:1361
2[2]Jaffe E,Harris N,Diebold J,et al.World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:A progress report.Am J Clin Pathol,1999,111(Suppl 1):S8
3[3]Ghielmini M,Schmitz S,Cogliatti S,et al.Prolonged treatment with 2-monthly rituximab significantly improves eventfree survival and duration of response in patients with follicular lymphoma:A randomized SAKK Trial.Blood,2002 (Abstr),100:161A
4[4]Witzig T,Vukov A,Habermann T,et al.Rituximab therapy for patients with newly diagnosed,asymptomatic advancedstage follicular gradel non-Hodgkin's lymphoma (NHL):A phase Ⅱ trial in the the North Central Cancer Treatment Group(NCCTG).Blood,2002 (Abstr),100:361A
5[5]Solal-Celigny P,Salles GA,Brousse N et al.Single 4-dose rituximab treatment for low tumor burden lymphoma (FL):Survival analyses with a follow-up (F/Up) of at least 5 years.Blood,2004,104 (Abstr):585
6[6]Hiddemann W,Forstpointner R,Kneba M,et al.The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma:Results of two prospective randomized studies of the German Low Grade Lymphoma Study (GLSG).Blood,2004,Abstract # 161
7[7]McLaughlin P,Grillo-López A,Link B,et al.Rituximab Chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:Half of patients respond to a four-dose treatment program.J Clin Oncol,1998,16:2825
8[8]Marcus R,Hagenbeek A,Eghbali H,et al.Fludarabine versus CVP in newly diagnosed patients with stages Ⅲ/Ⅳ nonHodgkin's Lymphoma:Final analysis of prospective randomized phase Ⅲ intergroup study.Ann Oncol,2002,13 (Suppl.2):181 (Abstr)
9[9]Zinzani PL,Pulsoni A,Perrotti A,et al.Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.J Clin Oncol,2004,22:2662
10[10]Czuczman M,Fallon A,Mohr A,et al.Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.Semin Oncol,2002,29 (Suppl 2):36
